Introduction
============

The gut microbiota (microbiome) form a complex and dynamic ecosystem that constantly interacts with host metabolism ([@b29]; [@b37]; [@b18]). The microbiome provides trophic ([@b37]) and protective ([@b83]) functions and impact on the host\'s energy metabolism ([@b72]), facilitating the absorption of complex carbohydrates (fiber breakdown) and influencing the homeostasis of amino acids ([@b38]). For example in humans, 1--20% of the circulating plasma lysine and threonine are derived from gut bacterial synthesis ([@b56]). The microbiota also synthesize essential vitamins such as vitamin K ([@b38]) and group B vitamins ([@b21]). These close symbiotic relationships are the result of co-evolutionary processes, through which natural selection has promoted the host genotypes that provide well-adapted adhesion sites for specific microorganisms ([@b9]). In total, the mammalian symbiotic superorganism can contain significantly more active DNA in the fan of genes from the microbiome than in the host genome ([@b66]). Indeed, the symbiotic microbiotal speciation of some invertebrates (e.g. plataspid insects) has been shown to be closely connected with host evolution and take control of many metabolic functions resulting in host genome reduction ([@b39]). The indigenous microbiota of mammals also strongly influences the metabolism of many drugs and nutrients, modifying both their bioavailability and metabolic fate ([@b66]). For example, phytoestrogens are metabolized into active compounds by gut microbiota ([@b75]; [@b6]). But despite their evident important contribution to host biology and function, some bacterial species contained in the gut also have the potential to generate carcinogens or can be the source of opportunistic infections ([@b15]). For instance, *Helicobacter pylori* is well known to be part of the commensal flora of the stomach that can cause gastritis, gastric ulcers and, in some cases, gastric cancer ([@b4]).

We have recently demonstrated a close relationship between the metabolism of gut microbiota and the susceptibility of rodents to insulin resistance in high-fat diet studies ([@b27]). In this context, recent works have shown that even subtle changes in the gut microbiota have an impact on the host phenotype ([@b36]; [@b69]; [@b70]). Other investigations have demonstrated the close link between obesity and gut microbiota in human and mice ([@b8], [@b10]; [@b45]; [@b79]).

Germ-free (GF) animal studies have been widely used as a source of knowledge on the gut microbiota contributions to host homeostatic controls ([@b91]). GF mice display unusual gut morphology, i.e. larger cecum, thinner intestinal villi, when compared with conventional animals as well as physiological and immunological abnormalities, i.e. lower peristalsis, decreased inflammatory responses ([@b15]). GF animals have also been used to observe the developmental mechanisms of the gastrointestinal tract in interaction with the gut microbiota ([@b13]). However, despite the extensive use of GF models, the exact mechanisms involved in the morphologic, physiologic and immunologic modifications in GF animals remain unclear. The characterization of the metabolic differences between conventional and GF mice is, therefore, an essential step toward better understanding the interaction between host and gut microbiota.

Metabonomic approaches combining spectroscopic profiling techniques with pattern recognition analysis have proved useful in the assessment of the systemic metabolic responses of organisms to drugs or nutrients ([@b64]; [@b47]; [@b28]; [@b68]). This approach has been successfully applied on biofluids and intact intestinal tissues in rodents to demonstrate the involvement of microbiota in the mammalian metabolism ([@b62]; [@b86]; [@b51]). In addition, metabonomic approaches have been recently used to demonstrate that hippurate excretion, a marker of gut microbiotal activity in protein catabolism to benzoate, varies between normal and obese rats ([@b90]) and the close link between gut microbiota and fatty liver phenotype in insulin-resistant mice ([@b27]).

In the current study, we employed a high-resolution ^1^H NMR spectroscopic approach to investigate the metabolic phenotype, or metabotype ([@b32]), of GF mice from urine and tissues (gut, liver and kidney) and to determine the biochemical consequences of the absent microbiome on these biological matrices.

Results
=======

Spectra from biofluids and tissue aqueous extracts contain prominent signals from metabolites representing numerous major metabolic pathways. For each analyzed biological matrix, a typical spectrum obtained from a conventional and a GF mouse is displayed ([Figures 1A and B](#f1){ref-type="fig"}, [2A and B](#f2){ref-type="fig"}, [3A and B](#f3){ref-type="fig"}, [4A and B](#f4){ref-type="fig"} and [5A and B](#f5){ref-type="fig"}) and [Table I](#t1){ref-type="table"} shows the NMR assignment and corresponding resonance multiplicity. The summaries of all statistical models are shown in [Table II](#t2){ref-type="table"}. The main metabolic differences in GF group were summarized for all biological matrices in [Table III](#t3){ref-type="table"}.

Urine
-----

The urine profile was characterized by high levels of taurine, 2-oxoglutarate, trimethylamine (TMA), citrate and succinate as previously reported ([@b17]) ([Figure 1A and B](#f1){ref-type="fig"}). The urinary profile of GF mice was characterized by low levels of hippurate, phenylacetylglycine (PAG), phenolic metabolites, 4-hydroxypropionic acid (4-HPP), 3-hydroxycinnamic acid (3-HCA) and *N*-acetylated glycoprotein signal and a marked high level of creatinine ([Figure 1C](#f1){ref-type="fig"}).

Liver
-----

Glucose resonances (δ 3.25--3.84) were predominant in the liver profile, which was also dominated by high levels of taurine and trimethylamine-*N*-oxide (TMAO) ([Figure 2A and B](#f2){ref-type="fig"}). The oxidized glutathione (GSSG) pattern was readily identified in the one-dimensional (1D) spectrum. It is possible to differentiate between the reduced (GSH) and the oxidized (GSSG) forms of glutathione by 2D NMR because the resonances of the magnetically non-equivalent protons of the cysteine β-CH~2~ residue in GSH (δ 2.95) shift to high frequency in GSSG (δ 3.29 and 2.95) ([@b42]). The statistical model built from all liver spectra displayed an outlier in the GF group (data not shown). This highly dilute sample was removed from the subsequent analysis and the model was recalculated with four individuals in the GF group against five individuals in the conventional group. The metabolite profile of the liver from GF mice exhibited significant higher levels of TMAO and phosphocholine. Not significant higher levels of tauro-conjugated bile acids and glycine were noted in the GF mouse profile ([Figure 2C](#f2){ref-type="fig"}). In addition, a lower level of GSSG together with a higher level of hypotaurine was observed in the liver of two GF animals.

Kidney
------

The kidney ^1^H NMR profiles were dominated by osmoprotectant compounds such as *myo*-inositol, glycine, betaine, choline and taurine ([@b93]) ([Figure 3A and B](#f3){ref-type="fig"}). The metabolite profile of the kidney from GF mice was characterized by higher levels of betaine, choline, *myo*-inositol, *scyllo*-inositol, ethanolamine, inosine and an unknown compound (U1) in the aromatic region of the spectra (δ 7.14 (d) and δ 7.30 (d)) ([Figure 3C](#f3){ref-type="fig"}).

Gut compartments
----------------

Duodenum, jejunum and ileum were all characterized by high levels of tyrosine when compared with the other tissue extracts ([Figure 4A, B](#f4){ref-type="fig"}; [Supplementary Figures S1A and B, and S2A and B](#S1){ref-type="supplementary-material"}) together with creatine and taurine, a feature shared with the colon ([Figure 5A and B](#f5){ref-type="fig"}). The colonic metabolite profile was characterized by high levels of *myo*-inositol and *scyllo*-inositol, as previously described ([@b52]) ([Figure 5A](#f5){ref-type="fig"}). Globally, these gut profiles also displayed similar patterns to those observed in human biopsies ([@b85]). Tauro-conjugated bile acids were observed only in duodenum, ileum and jejunum profiles.

Aqueous extract profiles of gut tissues from GF mice were markedly different to those from conventional mice ([Figures 4C](#f4){ref-type="fig"} and [5C](#f5){ref-type="fig"}; [Supplementary Figures S1C and S2C](#S1){ref-type="supplementary-material"}). The metabolite profile of the duodenum from GF mice was mainly characterized by higher levels of tauro-conjugated bile acids and alanine and lower levels of glycerophosphocholine (GPC) when compared with conventional mice ([Supplementary Figure S1C](#S1){ref-type="supplementary-material"}). Two highly diluted samples in the jejunum profiles of the GF group were outliers and hence orthogonal projection on latent structures (O-PLS-DA) correlation coefficients (*r*^2^) were not significant ([Supplementary Figure S2C](#S1){ref-type="supplementary-material"}). However, the GF group had higher levels of creatine and tauro-conjugated bile acids and lower levels of tyrosine in the jejunal tissue ([Supplementary Figure S2C](#S1){ref-type="supplementary-material"}). The ileum of GF mice was also characterized by a higher level of tauro-conjugated bile acids and lower levels of glutamate, fumarate, lactate, phosphocholine and alanine when compared with the ileum from conventional mice ([Figure 4C](#f4){ref-type="fig"}). Finally, when compared with conventional mice, the metabolite profile of the colon from GF mice revealed a higher level in a complex carbohydrate identified as raffinose ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}), and lower levels of lactate, creatine, 5-aminovalerate, propionate, glutamine, *myo*-inositol, *scyllo*-inositol ([@b60]), GPC, phosphocholine, choline, formate, uracil and fumarate ([Figure 5C](#f5){ref-type="fig"}).

Discussion
==========

In this study, the metabotypes derived from different biological matrices from GF and conventional mice were characterized ([@b64]; [@b47]) and it was showed that the metabolic impact of the microbiota extended beyond the intestinal tissue and biofluids to major organs such as the liver and kidney.

Evidence of gut microbiota re-processing of dietary metabolites
---------------------------------------------------------------

A major source of the intestinal metabolites is produced from dietary nutrients by both the intestinal cells and the gut microbiota. This production occurs mainly in the first 25% of the small intestine for amino acids, and in cecum and colon for fatty acids ([@b38]). Here, metabolic variations in response to gut microbial activity are observed in the biochemical profiles of intestinal tissue extracts with increasing effect along the continuous gastrointestinal tract. More specifically, it was observed that duodenum and jejunum displayed fewer metabolic differences between GF and conventional mice, whereas ileum and particularly colon were the most affected ([Table III](#t3){ref-type="table"}). This reflects the higher microbial loads found in ileum and colon ([@b29]). In particular, 5-aminovalerate was not observed in colon aqueous extract profiles of GF animals, which is consistent with its reported characterization as a product of protein degradation by several anaerobic bacteria, particularly clostridial strains ([Figure 5C](#f5){ref-type="fig"}) ([@b11]; [@b12]). 5-Aminovalerate is degraded to acetate, ammonia and propionate. A higher concentration of propionate also observed in colon profile of conventional mice is consistent with the higher concentration of 5-aminovalerate.

More evidence of the crucial role of gut bacteria in the digestion of dietary nutrients is seen in the lower urinary level of several microbial co-metabolites (hippurate, 4-HPP and 3-HCA) in GF mice ([Figure 1C](#f1){ref-type="fig"}). Indeed, it has been reported that gut microbiota are able to metabolize polyphenols, such as chlorogenic acids, into more absorbable compounds such as 4-HPP, 3-HCA and benzoic acid ([@b34]; [@b49]). Benzoic acid is then detoxified through conjugation with glycine in the liver and the kidney to form hippurate (benzoylglycine), a more hydrophilic metabolite that is then secreted by the renal tubular cells and excreted in the urine ([@b34]; [@b89]; [@b62]). Another microbial co-metabolite, PAG, was also found in lower concentration in the urinary profile of GF animals ([Figure 1C](#f1){ref-type="fig"}), illustrating that microorganisms are crucial actors in the production of these urinary metabolites through the modulation of food processing.

Evidence of the host--gut bacterial metabolic interaction: bile acid co-metabolism
----------------------------------------------------------------------------------

The metabolism and synthesis of the major bile acids are another example of mammalian--microbiotal co-metabolism that has been reported recently as crucial in determining the host phenotype ([@b50]). In the present study, the metabolite profiles of duodenum, jejunum and ileum ([Figure 4C](#f4){ref-type="fig"}) were all characterized by a higher concentration of tauro-conjugated bile acids in GF mice, which is not apparent in the colon profile ([Figure 5C](#f5){ref-type="fig"}). In conventional animals, tauro- and glycine-conjugated bile acids are deconjugated by gut microbiota, facilitating their fecal elimination. Here, in the absence of microorganisms, primary bile acids are reabsorbed into the enterohepatic cycle, without deconjugation, by passive diffusion in duodenum and jejunum and by active transport in the terminal part of the ileum ([@b15]; [@b40]) [](#f6){ref-type="fig"} ([Figure 7](#f7){ref-type="fig"}). This increased recycling of bile acids is also suggested by the significantly higher level of phosphocholine and by the observed trend of higher concentration of bile acids in the liver metabolic profile of GF mice ([Figure 2C](#f2){ref-type="fig"}). In fact, phosphocholine is the source of phosphatidylcholine, the most common phospholipid in bile, and its secretion is under control of certain bile acids, mainly cholic acid and deoxycholic acid, in hepatocytes ([@b80]; [@b3]; [@b35]). Thus, the observation of the higher level of phosphocholine in liver GF profile may be the result of either a modification of bile acid profile or a higher level of bile acids in hepatocytes.

Microbial modification of bile acid metabolism may have many biological consequences, as bile acids participate in the regulation of dietary lipid absorption and cholesterol metabolism. They also function as signaling molecules linking to a G-protein-coupled receptor family ([@b41]; [@b43]) or directly triggering the farnesoid X receptor (FXR), which is a hepatocyte nuclear receptor involved in the regulation of lipid and glucose metabolism ([@b48]; [@b22]; [@b59]). Bile acids exert strong influences on the regulation of the expression of some cytochrome *P*450 (CYP) detoxification enzymes in the liver ([@b40]). It is also well known that CYP are key enzymes in the production of bile acids from cholesterol ([@b71]). Furthermore, Gram-negative bacteria produce endotoxins (lipopolysaccharides) that affect the expression of some CYP enzymes in the liver ([@b81]). Thereby, the microbiota may have an impact on host energy homeostasis by participating, directly or indirectly, in the control of bile acid metabolism.

Evidence of the modulation of host cell pathways and physiology by gut microbiota
---------------------------------------------------------------------------------

The colonic metabolite profile in GF mice was characterized by lower levels of choline and its phosphorylated derivatives, GPC and phosphocholine. This is likely due to the disturbance of the membrane of colonocytes in GF animals. The observed accumulation of raffinose in these cells is probably also a consequence of this disruption. Raffinose is an oligosaccharide that is only digested by the gut microbiota, as monogastric animals do not express pancreatic α-galactosidase ([@b44]). In GF animals, it seems that this trisaccharide is able to cross the epithelial membrane and accumulates in colonocytes where it induces a rise in osmotic pressure. This phenomenon provokes a well-described signaling cascade that leads to the release of the mobile osmolytes, GPC, *myo*-inositol and *scyllo*-inositol ([@b88]; [@b2]) ([Figure 6](#f6){ref-type="fig"}). Interestingly, lower levels of these metabolites have previously been associated with human colon adenocarcinoma ([@b60]), and have also been observed in the brain of patients with hepatic encephalopathy ([@b46]; [@b1]) or associated with osmoregulatory function in the brain in response to atrophy ([@b78]). These physiological changes were correlated with significantly lower creatine concentrations that can be associated with lower energy demands and with a lower peristalsis due to an impaired function of the smooth muscle layer in GF mice ([@b15]). Furthermore, a number of metabolites involved directly (e.g. fumarate) or indirectly (e.g. glutamate, aspartate, alanine and lactate) in energy pathways were present at lower levels in the ilial and colonic epithelium. Aspartate and fumarate are also key metabolites in the metabolism of urea associated with the citric acid cycle, a pathway that enables the elimination of ammonia produced endogenously from the catabolism of amino acids, and exogenously from the degradation of proteins by gut microflora ([@b57]) ([Figure 7](#f7){ref-type="fig"}). The massive production of exogenous ammonium in colon lumen results in a high intake of ammonium in colonocytes where it is partially detoxified into urea ([@b61]). Thus, it is assumed that the observed lower levels of fumarate, glutamate, aspartate, alanine and lactate in GF profiles reflect the lower input of ammonia and/or the lower smooth muscle activity in these animals. All of these perturbations emphasize the fundamental role of gut microbiota in colonic epithelial metabolism.

Moreover, the liver metabotype of GF animals indicated other bacterial-related changes. A lower level of GSSG, the oxidized form of the powerful antioxidative compound GSH ([@b54]) and a higher level of hypotaurine were observed in two GF animals of a total of four ([Figure 2C](#f2){ref-type="fig"}). Despite the restricted numbers of individuals included in this study, it is possible that a subgroup of animals may exist. GSSG represents 1% of the total amount of glutathione *in vivo* ([@b26]). In this study, GSH was not observed because it is readily oxidized to GSSG by exposure to atmospheric oxygen during sample preparation. Thus, it can be considered that the observed GSSG reflects the whole amount of glutathione in the liver extract. Normally, glutathione, rather than hypotaurine, is the predominant antioxidative molecule in the liver. Furthermore, it has been demonstrated that hypotaurine is also a strong antioxidative compound ([@b5]; [@b93]). The observation of a high level of hypotaurine concomitant with low level of glutathione indicates a perturbation of the cell response to oxidative stress. Thus, for these two individuals, the higher level of hypotaurine may compensate for the lack of glutathione in the liver. It is noteworthy that the low total glutathione content was associated in these two animals with high levels of glycine, which is an essential amino acid for glutathione biosynthesis ([@b55]). Taken together, these observations indicate a perturbed γ-glutamyl cycle activity in the liver of two GF mice and this may be suggestive of altered cysteine metabolism ([@b53]). The low level of total glutathione in GF animals may impact on many metabolic pathways as it is also a coenzyme involved in the regulation of protein synthesis and degradation, as well as in the mechanism of immune system and in the prostaglandin metabolism ([@b54]; [@b25]; [@b82]; [@b84]).

TMAO variation contributes to the statistical separation between the metabolic profiles of livers from GF and conventional mice ([Figure 2C](#f2){ref-type="fig"}). TMAO was expected to be lower in GF animals as previously observed in urine profiles during re-colonization of GF rats ([@b62]). Here, we observed a significantly higher level of TMAO in GF mice. TMAO in the liver derives either from a direct absorption of TMAO contained in the diet, from the gut microbial processing of choline and carnitine, or is endogenously synthesized by the oxidation of TMA to TMAO by the flavin-containing mono-oxygenase isomer 3 (FMO3) ([@b76]; [@b94]). As the two groups were fed exactly the same diet, it can be deduced that the higher level of TMAO found in the liver of GF animals comes from either a greater uptake of TMA/TMAO contained in the diet, or from a higher endogenous synthesis. In contrast to humans, expression of FMO3 in mouse is sex dependent with a much lower expression in males. However, it has been recently demonstrated that this expression is highly inducible by TCDD (dioxin) in an aryl hydrocarbon receptor-dependent manner ([@b77]). Thus, it is possible that FMO3 in male GF animals was induced.

A lower level of N-acetylated glycoprotein (Nac) signal was observed in the urine of GF animals ([Figure 1C](#f1){ref-type="fig"}). This signal comes from the most abundant glycoprotein in urine, the Tamm--Horsfall protein (THP), also known as uromodulin, a small glycoprotein (∼90 kDa) secreted by the thick ascending limb of the Henle\'s loop of the nephron ([@b74]). This protein is of particular interest in that its role is associated with the prevention of urinary tract infections. The N-glycans at the protein surface bind to uropathogenic strains of *Escherichia coli*, preventing the adhesion of these pathogens to the bladder wall ([@b67]; [@b58]). Here, the observed lower levels of Nac in GF urine profiles may be caused by a lower amount of THP in the urine or by a lower glycosylation of the protein. The protective function of THP is driven by N-glycans, so this observation reveals that protection against urinary tract pathogens is affected in the absence of gut microbiota. Also, choline, betaine, *myo*-inositol and *scyllo*-inositol were elevated in kidneys from GF mice ([Figure 3C](#f3){ref-type="fig"}). All these metabolites are osmoprotectants ([@b19]) and it has been shown that their level increases in kidney cells when the environment becomes hypertonic ([@b92]; [@b19]; [@b14]; [@b20]). Both decrease in THP concentration in urine and hypertonicity of interstitial fluid in kidney have been associated with renal dysfunction ([@b73]), but it was not possible in this study to establish a link between these two observations.

Finally, the observed increased excretion of creatinine, a biomarker of muscle mass, in the urine of GF mice ([Figure 1](#f1){ref-type="fig"}) is likely related to the lean phenotype of GF mice, as confirmed in a recent study ([@b10]). Collectively, these data demonstrate that gut microbiota have a function in the control of the metabolic phenotype of the colon and liver and influence the whole-body metabolic homeostasis of the host.

Conclusions
===========

We have demonstrated that gut microbiotal activities have an impact on site-specific intestinal epithelial biochemistry and influence at 'long-range\' hepatic and renal metabolite profiles as well as the global metabolic phenotype of the host (summarized in [Figure 7](#f7){ref-type="fig"}). It would be of considerable interest to correlate the compartmentalized metabolite profiles with the known bacterial strains that compose the microbiota and this is the focus of an ongoing investigation. Gut microbiota seem to be an important regulator of the bile acid metabolism and may have an impact on CYP enzyme induction status. These results also suggest the potential impact of the gut microbiota on antioxidant mechanisms in the liver but further studies are needed. We also show that gut microbiome influences the renal metabolite profile possibly in response to interstitial hypertonicity. By acting directly or indirectly on the metabolism of liver and kidney, key organs of body physiology (i.e. homeostasis of arterial pressure and equilibrium of cholesterol and electrolyte levels), the gut microbiota can be considered as a major contributor of host homeostasis. Improved knowledge of host--microbiome interactions will lead to a better understanding of individual variation in relation to health status and interventional outcomes ([@b23]; [@b63]).

Materials and methods
=====================

Animal handling and sample preparation
--------------------------------------

All studies were conducted according to the Swiss legislation on animal experimentation.

One group of five GF C3H/HeJ mice (Charles River, France) was maintained in isolators on γ-ray-irradiated food (R03-10) and γ-ray-irradiated water, whereas the other group of five conventional C3H/HeJ mice was maintained under identical conditions but in a conventional environment with non-irradiated food and water. Isolators were checked every week for any bacterial contamination throughout the life of GF animals. Throughout the duration of the study, water and food were provided *ad libitum*. Mice were euthanized when they were 8 weeks old, at which time urine and organs (duodenum, jejunum, ileum, colon, liver and kidney) were collected. Samples were snap frozen in liquid nitrogen and stored at −80°C until analysis.

^1^H NMR spectroscopy
---------------------

Urine samples were freeze-dried and dissolved in 50 μL of phosphate buffer 0.2 M (pH 7.4) in D~2~O plus 0.05% sodium 3-(tri-methylsilyl)propionate-2,3-d4 (TSP) before transferring to capillary tubes for analysis by ^1^H NMR spectroscopy.

Tissue samples were homogenized and extracted in acetonitrile/water (1:1), as previously described ([@b87]). The supernatant containing the aqueous phase was collected, freeze-dried and dissolved in 600 μl of D~2~O. Samples were centrifuged for 10 min at 15 000 *g*, and 500 μl of the supernatant and 50 μl of water were used for later analysis by NMR spectroscopy.

All ^1^H NMR spectra were acquired on a Bruker Avance 600 MHz Spectrometer (Bruker Analytische GmbH, Rheinstetten, Germany) operating at 600.13 MHz and using a standard 1D pulse sequence ([@b65]) (recycle delay (RD)--90°--*t*~1~--90°--*t*~m~--90°--acquire free induction decay (FID)) with water suppression applied during RD of 2 s and mixing time (*t*~m~) of 100 ms and a 90° pulse set at 9.75 μs. Spectra were acquired using 256 scans into 32K data points with a spectral width of 12 000 Hz. The FIDs were multiplied by an exponential function corresponding to 0.3 Hz line broadening. Zero filling of a factor of four for all tissue extracts and two for urine samples was also applied to the FIDs. All spectra were manually phased, baseline corrected and calibrated to lactate (δ 1.33) for tissue extracts and to TSP (δ 0.00) for urine samples. Metabolites were assigned using data from literature ([@b65]; [@b30]; [@b31]) and additional two-dimensional (2D) NMR experiments on selected samples.

The 2D ^1^H--^1^H NMR spectra were performed on a Bruker DRX 400 Spectrometer operating at 400.13 MHz (Bruker Analytische GmbH) using 2D correlation spectroscopy ([@b7]) and total correlation spectroscopy ([@b33]) experiments. 2D ^1^H--^13^C heteronuclear single quantum coherence NMR ([@b16]) was performed on liver aqueous extracts on a Bruker DRX 500 Spectrometer operating at 499.9 MHz (Bruker Analytische GmbH) equipped with a 5 mm ^1^H--^13^C inverse cryoprobe.

Data analysis
-------------

To eliminate the variability in water resonance presaturation, the chemical shift region between δ 4.66 and 4.88 was removed from all spectra before statistical analysis, except for liver where to avoid bias due to baseline distortion, the region between δ 4.77 and 5.38 was removed. As previously described ([@b24]), all data were analyzed on full-resolution spectra (35 600 data points for liver and 36 500 data points for all other tissue extracts), normalized to the total peak area and models were constructed using O-PLS-DA with unit variance scaling on Matlab 7.0.1 software (The MathWorks Inc.). Despite the use of phosphate buffer, many urine spectra still displayed subtle pH-dependent shifts; therefore, the O-PLS-DA was performed on larger bins of 0.005 p.p.m. (1750 bucketed points) to minimize minor frequency changes in spatial components.

To aid interpretation, the O-PLS coefficients were plotted into a spectral domain using the back-scaling method ([@b24]). Using this method, the weights of each variable are back-scaled to their initial metric of the data and then the shape of NMR spectra and the sign of the coefficients are preserved. However, the weights of the variables can still be compared using a colour code corresponding to the square of the actual O-PLS coefficients. By construction, the O-PLS coefficients are directly proportional to the correlation coefficients between the discriminant axis and the NMR data. For this reason, the square of the coefficients can be represented in terms of correlation after applying the same corrective factor to all coefficients, allowing by this way an estimation of the amount of variance of each NMR variable involved in the discrimination.
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![^1^H NMR spectra (600 MHz) of urine samples from germ-free (GF) (**A**) and conventional (**B**) mice. The aromatic region (δ 6.5--9.0) has been vertically expanded × 4. (**C**) Plot of O-PLS-DA coefficients related to the discrimination between ^1^H NMR spectra of urine from GF (top) and conventional (bottom) mice. For identification of the peak numbers, refer to codes in [Table II](#t2){ref-type="table"}.](msb200856-f1){#f1}

![^1^H NMR spectra (600 MHz) of liver aqueous extracts of germ-free (GF) (**A**) and conventional (**B**) mice. The aromatic region (δ 6.5--9.0) has been vertically expanded × 4. (**C**) Plot of O-PLS-DA coefficients related to the discrimination between ^1^H NMR spectra of urine from GF (top) and conventional (bottom) mice. For identification of the peak numbers, refer to codes in [Table II](#t2){ref-type="table"}.](msb200856-f2){#f2}

![^1^H NMR spectra (600 MHz) of kidney aqueous extracts of germ-free (GF) (**A**) and conventional (**B**) mice. The aromatic region (δ 6.5--9.0) has been vertically expanded × 4. (**C**) Plot of O-PLS-DA coefficients related to the discrimination between ^1^H NMR spectra of urine from GF (top) and conventional (bottom) mice. For identification of the peak numbers, refer to codes in [Table II](#t2){ref-type="table"}.](msb200856-f3){#f3}

![^1^H NMR spectra (600 MHz) of ileum aqueous extracts of germ-free (GF) (**A**) and conventional (**B**) mice. The aromatic region (δ 6.5--9.0) has been vertically expanded × 4. (**C**) Plot of O-PLS-DA coefficients related to the discrimination between ^1^H NMR spectra of urine from GF (top) and conventional (bottom) mice. For identification of the peak numbers, refer to codes in [Table II](#t2){ref-type="table"}.](msb200856-f4){#f4}

![^1^H NMR spectra (600 MHz) of colon aqueous extracts of germ-free (GF) (**A**) and conventional (**B**) mice. The aromatic region (δ 6.5--9.0) has been vertically expanded × 4. (**C**) Plot of O-PLS-DA coefficients related to the discrimination between ^1^H NMR spectra of urine from GF (top) and conventional (bottom) mice. For identification of the peak numbers, refer to codes in [Table II](#t2){ref-type="table"}.](msb200856-f5){#f5}

![Variation of raffinose metabolism by colonocytes in germ-free (GF) and conventional microbiome animals. In conventional animals, raffinose is first digested by microbial α-galactosidase to release galactose and sucrose. Then, the mammalian invertase attached to the brush border releases glucose and fructose from sucrose. These monosaccharides are then utilized as a source of carbon for bacterial fermentation. In GF animals, raffinose is not catabolized and passive diffusion into colonocytes may occur contributing to the osmotic pressure that is regulated by decreasing levels of the mobile osmolytes: glycerophosphocholine, *myo*-inositol and *scyllo*-inositol. GPC, glycerophosphocholine; SCFAs, short chain fatty acids.](msb200856-f6){#f6}

![Summary of some of the major systemic effects of the gut microbiome on mouse metabolism in different compartments. Metabolites observed in this study are shown in red when their level is higher in GF profiles or in green when it is lower. The enterohepatic cycle of bile acids is shown as blue arrows. The citric acid cycle has been simplified for clarity.](msb200856-f7){#f7}

###### 

Full ^1^H NMR chemical shift data for discriminating metabolites assigned in urine and tissue samples (note that signals for unassigned or non-significantly discriminating metabolites are not reported)

  Code   Metabolite                          δ ^1^H (multiplicity) group                                                                                                                                  Compartments observed
  ------ ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------
  1      2-Oxoisocaproate                    0.94 (d) CH~3~, 2.18 (m) CH, 2.64 (d) CH~2~                                                                                                                  U
  2      2-Oxoglutarate                      2.47 (t) γCH~2~, 3.03 (t) βCH~2~                                                                                                                             U
  3      [D]{.smallcaps}-3-Hydroxybutyrate   1.20 (d) CH~3~, 2.31 (dd) ½ αCH~2~, 2.41 (dd) ½ αCH~2~, 4.16 (dt) CH                                                                                         L
  4      3-Hydroxycinnamate                  6.49 (d) αCH, 6.92 (d) H2, 7.09 (s) H6, 7.17 (d) H4, 7.33 (m) H3/β-CH                                                                                        U
  5      4-Hydroxyphenylpropionate           2.52 (t) αCH, 2.91 (t) βCH, 6.92 (d) H2/H6, 7.22 (d) H3/H5                                                                                                   U
  6      5-Aminovalerate                     1.64 (m) β/γCH~2~, 2.25 (t) αCH~2~, 3.02 (t) δCH~2~                                                                                                          C
  7      5-Hydroxytryptophan                 3.23 (dd) ½ βCH~2~, 3.41 (dd) ½ βCH~2~, 4.02 CHNH~2~, 6.88 H6, 7.14 H2, 7.28, 7.41 H7                                                                        U
  8      Acetate                             1.92 (s) CH~3~                                                                                                                                               U, L, K, D, J, I, C
  9      Adenosine diphosphate               4.20 (dd) ½ CH~2~, 4.23 (dd) ½ CH~2~, 4.27 (dt) H5, 4.50 (m) H4, 4.77 (m) H3, 6.12 (d) H2, 8.18 (s) H7, 8.50 (s) H12, 8.55 (s) H12                           L, K
  10     Alanine                             1.48 (d) βCH~3~, 3.79 (m) CH                                                                                                                                 L, K, D, J, I, C
  11     Aspartate                           2.68 (AB of ABX) ½ βCH~2~, 2.82 (AB of ABX) ½ βCH~2~, 3.91 (X of ABX) αCH                                                                                    K, D, J, I, C
  12     Betaine                             3.27 (s) CH~3~, 3.90 (s) CH~2~                                                                                                                               K
  13     Bile acids (mixed)                  0.70 (s) CH~3~, 1.05 (s) CH~3~                                                                                                                               L, D, J, I
  14     Choline                             3.20 (s) N-(CH~3~)~3~, 3.51 (t) βCH~2~, 4.05 (t) αCH~2~                                                                                                      L, K, D; J, I, C
  15     Citrate                             2.69 (AB) ½ CH~2~, 2.55 (AB) ½ CH~2~                                                                                                                         U
  16     Creatine                            3.03 (s) N-CH~3~, 3.94 (s) CH~2~                                                                                                                             U, K, D, J, I, C
  17     Creatinine                          3.06 (s) N-CH~3~, 4.05 (s) CH~2~                                                                                                                             U
  18     Dimethylamine                       2.72 (s) CH~3~                                                                                                                                               U
  19     Ethanolamine                        3.13 (t) NH-CH~2~, 3.83 (t) HO-CH~2~                                                                                                                         K
  20     Formate                             8.46 (s) CH                                                                                                                                                  U, D, J, I, C
  21     Fumarate                            6.52 (s) CH                                                                                                                                                  U, L, K, D, J, I, C
  22     α-Glucose                           3.42 (t) H4, 3.54 (dd) H2, 3.71 (t) H3, 3.72 (m) ½ CH~2~-C6, 3.76 (m) ½ CH2-C6, 3.83 (ddd) H5, 5.23 (d) H1                                                   L, K, D, J, I, C
  23     β-Glucose                           3.24 (dd) H2, 3.40 (t) H4, 3.47 (ddd) H5, 3.48 (t) H3, 3.84 (m) ½ CH~2~-C6, 3.90 (dd) ½ CH~2~-C6, 4.64 (d) H1                                                L
  24     Glutamate                           2.08 (m) βCH~2~, 2.34 (m) γCH~2~, 3.75 (m) αCH                                                                                                               K, D, J, I, C
  25     Glutamine                           2.15 (m) βCH~2~, 2.46 (m) γCH~2~, 3.77 (m) αCH                                                                                                               L, K, D, J, I, C
  26     Glutathione (oxidized)              2.17 (m) βCH~2~ Glu, 2.55 (m) γCH~2~ Glu, 2.98 (AB of ABX, broad) and 3.30 (AB of ABX, broad) βCH~2~ Cys, 3.78, αCH~2~ Gly, 4.75 (X of ABX, broad) αCH Cys   L
  27     Glycine                             3.56 (s) αCH                                                                                                                                                 U, D, J, I
  28     Glycerophosphocholine               3.23 (s) N-(CH~3~)~3~, 4.32 (m broad) CH                                                                                                                     D, J, C
  29     Glycogen                            3.83 (m broad), 5.41 (m broad)                                                                                                                               L
  30     Guanine                             7.72 (s) CH                                                                                                                                                  U
  31     Guanosine                           3.86 (m) CH~2~, 4.24 (m) H5, 4.41 (t) H4′, 5.91 (d) H2′, 8.00 (s) H8                                                                                         U, D, J
  32     Hippurate                           3.97 (d) CH~2~, 7.56 (t) m-CH, 7.65 (t) p-CH, 7.84 (d) αCH                                                                                                   U
  33     Histidine                           3.14 ½ βCH~2~ (AB of ABX), 3.25 ½ βCH~2~ (AB of ABX), 3.99 αCH (X of ABX), 7.08 (s) H5, 7.83 (s) H3                                                          L, K
  34     Hypotaurine                         2.64 (t) CH~2~-NH~2~, 3.37 (t) CH~2~-SO~3~                                                                                                                   L
  35     Inosine                             3.85 ½ CH~2~ (AB of ABX), 3.92 ½ CH~2~ (AB of ABX), 4.28 H5′ (X of ABX), 6.10 (d) H2′, 8.24 (s) H8, 8.34 (s) H2                                              L, K, D, J, I, C
  36     Isoleucine                          0.95 (t) δCH~3~, 1.01 (d) βCH~3~, 1.26 (m) ½ γCH~2~, 1.48 (m) ½ γCH~2~, 1.98 (m) βCH 3.68 (d) αCH                                                            U, L, K, D, J, I, C
  37     Isovaleric acid                     0.92 (d) CH~3~, 1.94 (m) CH, 2.05 (d) CH~2~                                                                                                                  U
  38     Lactate                             1.33 (d) βCH~3~, 4.12 (q) αCH                                                                                                                                L, K, D, J, I, C
  39     Leucine                             0.96 (d) δCH~3~, 1.71 (m) γCH, 3.73 (t) αCH                                                                                                                  L, K, D, J, I, C
  40     Lysine                              1.48 (m) γCH~2~, 1.73 (m) δCH~2~, 1.91 (m) βCH~2~, 3.03 (t) ɛCH~2~, 3.76 (t) αCH                                                                             K, D, J, I, C
  41     *myo*-Inositol                      3.29 (t) H5, 3.53 (dd) H1/H3, 3.63 (t) H4/H6, 4.06 (t) H2                                                                                                    K, D, J, C
  42     *N*-Acetylcysteine                  2.08 (s) CH~3~, 2.94 (m) CH~2~, 4.39 (m) CH                                                                                                                  U
  43     Nicotinurate                        3.99 (s) CH~2~, 7.6 (dd) H5, 8.25 (d) H4, 8.71 (d) H6, 8.94 (s) H2                                                                                           L, K
  44     Phosphocholine                      3.22 (s) N-(CH~3~)~3~, 3.62 (t) βCH~2~, 4.23 (m) αCH~2~                                                                                                      L, I, C
  45     Phenylacetylglycine                 3.67 (s) δCH~2~, 3.75 (d) αCH~2~, 7.35 (m) H2/H6, 7.37 (t) H4, 7.42 (m) H3/H5                                                                                U
  46     Phenylalanine                       3.13 ½ βCH~2~ (AB of ABX), 3.28 ½ βCH~2~ (AB of ABX), 4.00 αCH (X of ABX), 7.33 (m) H2/H6, 7.39 (t) H4, 7.43 (m) H3/H5                                       L, K, D, J, I, C
  47     Putrescine                          1.80 (m broad) βCH~2~, 3.05 (m broad) αCH~2~                                                                                                                 U
  48     Raffinose                           3.53 (s), 3.55--3.59 (m), 3.68 (s), 3.70--3.92 (m), 3.96 (t), 4.00--4.07 (m), 4.23 (d) H3 (fructose), 5.00 (d) H21 (galactose), 5.43 (d) H7 (glucose)        C
  49     *scyllo*-Inositol                   3.35 (s) CH                                                                                                                                                  C
  50     Succinate                           2.41 (s) CH~3~                                                                                                                                               U, L, K
  51     Taurine                             3.27 (t) CH~2~-SO~3~, 3.43 (t) CH~2~-NH                                                                                                                      U, L, K, D, J, I, C
  52     Trimethylamine                      2.86 (s) CH~3~                                                                                                                                               U
  53     Trimethylamine N-oxide              3.27 (s) (CH~3~)~3~                                                                                                                                          U, L
  54     Tyrosine                            3.06 ½ βCH~2~ (AB of ABX), 3.16 ½ βCH~2~ (AB of ABX), 3.94 αCH (X of ABX), 6.87 (d) H2/H6, 7.18 (d) H3/H5                                                    L, K, D, J, I, C
  55     Uridine diphosphate                 4.21 (dd) ½ CH~2~, 4.25 (dd) ½ CH~2~, 4.37 (dt) H5, 4.39 (dd) H4, 4.43 H3, 5.96 (m) H2, 5.98 (d) H10, 7.98 (d) H11                                           U, L
  56     Uracil                              5.78 (d) CH, 7.52 (d) CH                                                                                                                                     I, C
  57     Uridine                             3.81 (dd) ½ CH~2~, 3.92 (dd) ½ CH~2~, 4.12 (dt) H5, 4.24 (dd) H4, 4.36 (dd) H3, 5.88 (d) H10, 5.92 (m) H2, 7.88 (d) H11                                      L, K, D, J
  58     Uridine triphosphate                4.25 (dd) ½ CH~2~, 4.28 (dd) ½ CH~2~, 4.39 (dt) H5, 4.40 (dd) H4, 4.45(dd) H3, 5.90 (d) H10, 5.98 (m) H2, 7.98 (d) H11                                       L
  59     Valine                              0.99 (d) γCH~3~, 1.05 (d) γ′CH~3~, 2.28 (m) βCH, 3.62 (d) αCH                                                                                                L, K, D, J, I, C

The numbering/nomenclature of compounds follows the IUPAC system.

Key: s, singlet; d, doublet, dd, doublet of doublets; t, triplet; m, multiplet; ABX refers to second-order spin system usually of the form CH~2~CH where all three protons are non-equivalent; C, colon; D, duodenum; I, ileum; J, jejunum; K, kidney; L, liver; U, urine.

###### 

Summaries of O-PLS-DA statistical models

  Sample     Orthogonal component   *Q*^2^*Y*   *R*^2^*X*
  ---------- ---------------------- ----------- -----------
  Duodenum   0                      0.57        0.27
  Jejunum    1                      0.37        0.52
  Ileum      0                      0.46        0.26
  Colon      1                      0.70        0.34
  Liver      1                      0.58        0.47
  Kidney     1                      0.42        0.61
  Urine      1                      0.83        0.39

*Q*^2^*Y*, cross-validated predicted percentage of the response *Y*; *R*^2^*X*, variation of *X* explained by the model.

###### 

Summary of variations of metabolite signals with the highest discriminant power for each model

  Metabolite                    δ (p.p.m.)   Duodenum   Jejunum   Ileum   Colon   Liver   Kidney   Urine
  ----------------------------- ------------ ---------- --------- ------- ------- ------- -------- -------
  3-HCA                         7.07                                                               −0.93
  4-HPP                         6.89                                                               −0.92
  5-Aminovalerate               2.236                                     −0.86                     
  Alanine                       1.476        +0.84                −0.83                             
  Aspartate                     2.81                              −0.84                             
  Betaine                       3.904                                                     +0.98     
  Choline                       3.2052                                                    +0.94     
  Creatine                      3.04                    +0.52             −0.83                     
  Creatinine                    4.08                                                               +0.89
  Ethanolamine                  3.1448                                                    +0.87     
  Formate                       8.459                                     −0.76                     
  Fumarate                      6.520                             −0.79   −0.91                     
  Glutamate                     2.078                             −0.85                             
  Glutathione                   2.5528                                            −0.71             
  Glycine                       3.559                   +0.49                     +0.79             
  GPC                           3.2312       −0.85                        −0.85                     
  Hippurate                     7.84                                                               −0.93
  Hypotaurine                   2.645                                             +0.60             
  Inosine                       8.3468                                                    +0.88     
  Lactate                       1.336                             −0.79   −0.78                     
  Nac                           2.185                                                              −0.76
  *myo*-Inositol                3.5288                                    −0.76           +0.92     
  PAG                           7.38                                                               −0.87
  Phosphocholine                3.2252                                    −0.76   +0.93             
  Raffinose                     5.435                                     +0.86                     
  *scyllo*-Inositol             3.3485                                    −0.72           +0.78     
  Tauro-conjugated bile acids   0.697        +0.93      +0.51     +0.78           +0.66             
  TMAO                          3.269                                             +0.85             
  Tyrosine                      6.909                   −0.81                                       
  Uracil                        5.811                                     −0.94                     

Full chemical shift data for each metabolite are reported in [Table I](#t1){ref-type="table"}. The correlation coefficients with the discriminant axis for the metabolites involved in the difference between GF and conventional animals are presented as either higher (+) or lower level (−) compared with the conventional control.
